Quality by design approach for formulation development and evaluation of carboplatin loaded ethylcellulose nanosponges
Source abstract
Abstract
Nanosponges, porous nanocarriers were explored for encapsulation of carboplatin by employing a quality by design approach. Nanosponges were prepared by double emulsion solvent evaporation using the central composite design. Ethylcellulose, 450 mg, polyvinyl alcohol, 2.3% (w/v) and phase evaporation rate, 760 rpm yielded the optimized spherical particles of size 272.92 ± 12.31 nm, PDI 0.390, with zeta charge of −22.3 mV. The entrapment efficiency of carboplatin-loaded nanosponges was 56.27 ± 2.52%. A sustained carboplatin release of 79.03% and 95.94% within 12 h at pH 4.5 and 6.8, respectively suggested that nanosponges could be promising carriers for sustained release of hydrophilic therapeutic candidates.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems · Drug Solubulity and Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Punjab University College of Pharmacy, University of the Punjab, Lahore, Pakistan
References (41)
Show source-provided references
1. 10.1016/j.colsurfb.2016.02.02610.1016/j.colsurfb.2016.02.026 ↗
2. 10.1208/s12249-014-0139-210.1208/s12249-014-0139-2 ↗
3. 10.1208/s12248-012-9339-410.1208/s12248-012-9339-4 ↗
4. 10.1080/10717544.2016.120515810.1080/10717544.2016.1205158 ↗
5. 10.3109/03639045.2012.69461010.3109/03639045.2012.694610 ↗
6. Abdul A. H. · IJPSN · 2019 · 13 · 476610.37285/ijpsn.2020.13.1.5 ↗
7. Bolmal U. B. · PCI-Approved-IJPSN. · 2013 · 6 · 193410.37285/ijpsn.2013.6.1.3 ↗
8. 10.1016/j.jddst.2019.10130210.1016/j.jddst.2019.101302 ↗
9. ICH. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: quality risk management Q9. https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-3.pdf
10. ICH. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: pharmaceutical development Q8(R2). https://database.ich.org/sites/default/files/Q8_R2_Guideline.pdf
11. ICH. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: pharmaceutical quality systems (Q10). https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human_en.pdf
12. 10.1080/17425247.2018.150476810.1080/17425247.2018.1504768 ↗
13. 10.1208/s12249-015-0465-z10.1208/s12249-015-0465-z ↗
14. El-Habashy S. E. · Int. J. Nanomedicine. · 2016 · 11 · 2369
15. 10.2478/v10007-011-0022-610.2478/v10007-011-0022-6 ↗
16. 10.3109/10717544.2014.91676810.3109/10717544.2014.916768 ↗
17. 10.1208/s12249-009-9220-710.1208/s12249-009-9220-7 ↗
18. 10.3109/1083745100373928910.3109/10837451003739289 ↗
19. 10.18433/J3K30810.18433/J3K308 ↗
20. 10.1016/j.ijpharm.2015.10.05710.1016/j.ijpharm.2015.10.057 ↗
21. Aldawsari H. M. · Int. J. Nanomedicine. · 2015 · 10 · 89310.2217/nnm.14.236 ↗
22. 10.1016/j.ejps.2016.09.03810.1016/j.ejps.2016.09.038 ↗
23. 10.1016/B978-0-12-815799-2.00014-910.1016/B978-0-12-815799-2.00014-9 ↗
24. Lan Z. · J. Pharm. Sci. · 2017 · 12 · 1
25. 10.1208/s12248-013-9472-810.1208/s12248-013-9472-8 ↗
26. Nayak, A. K.; Ahmed, S. A.; Beg, S.; Tabish, M.; Hasnain, M. S. Application of Quality by Design for the Development of Biopharmaceuticals. In: Pharmaceutical quality by design. Academic Press: London, 2019; pp. 399–411. DOI: 10.1016/B978-0-12-815799-2.00019-8.10.1016/B978-0-12-815799-2.00019-8 ↗
27. 10.3109/978142007423910.3109/9781420074239 ↗
28. 10.3109/10717544.2014.94864310.3109/10717544.2014.948643 ↗
29. 10.1208/s12248-010-9185-110.1208/s12248-010-9185-1 ↗
30. 10.3390/polym1212290310.3390/polym12122903 ↗
31. 10.3109/03639045.2012.68105410.3109/03639045.2012.681054 ↗
32. 10.3109/03639045.2010.48726310.3109/03639045.2010.487263 ↗
33. 10.1023/B:PHAM.0000036917.75634.be10.1023/B:PHAM.0000036917.75634.be ↗
34. 10.1016/j.colsurfb.2003.10.00310.1016/j.colsurfb.2003.10.003 ↗
35. 10.1016/j.ajps.2015.09.00410.1016/j.ajps.2015.09.004 ↗
36. Tiwari A. · Am. J. Pharm. Tech. Res. · 2016 · 6 · 79
37. Pandav S. · J. Pharm. · 2014 · 2014 · 1
38. 10.1002/jps.260052121010.1002/jps.2600521210 ↗
39. 10.1016/S0928-0987(01)00095-110.1016/S0928-0987(01)00095-1 ↗
40. 10.1039/C7RA06829H10.1039/C7RA06829H ↗
41. 10.2147/DDDT.S24050610.2147/DDDT.S240506 ↗